Skip to main content
SpringerLink
Log in

Pharmacological issues relating to viral resistance

  • Published:
Infection Aims and scope Submit manuscript

Summary

Anti-HIV drug regimens can fail for a number of reasons including virological resistance, difficulties of adherence and poor tolerability. However, this brief review focuses on the development of “pharmacological” resistance as an area of great importance in drug failure. For nucleoside reverse transcriptase inhibitors (NRTIs) this is related to the possible down-regulation of the intracellular phosphorylation of an NRTI with time. For protease inhibitors the concern is cells expressing transmembrane energy-dependent transporters (such as p-glycoprotein, p-gp; or multi-drug resistance protein, MRP) which efflux drug (particularly protease inhibitors) out of the cell so that intracellular concentrations of drug are insufficient for antiviral effect.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Palella, F. J., Delaney, K. M., Moorman, A. C., Loveless, M. O., Fuhrer, J., Satten, G. A., Aschman, D. J., Holmberg, S. D.: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N. Engl. J. Med. 338 (1998) 853–860.

    Article  PubMed  Google Scholar 

  2. Hogg, R. S., Heath, K. V., Yip, B., Craib, K. J. P., O'Shaughnessy, M. V., Schechter, M. T., Montaner, J. S. G.: Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA 279 (1998) 459–454.

    Article  Google Scholar 

  3. Lavie, A., Schlichting, I., Vetter, I. R., Konrad M., Reinstein, J., Goody, R. S.: The botleneck in AZT activation. Nature 3 (1997) 922–924.

    Article  CAS  Google Scholar 

  4. Jacobsson, B., Britton, S., He, Q., Karlsson, A., Eriksson, S.: Decreased thymidine kinase levels in peripheral blood cells from HIV-seropositive individuals: implications for zidovudine metabolism. AIDS Res. Hum. Retroviruses 11 (1995) 805–811.

    PubMed  CAS  Google Scholar 

  5. Sommadossi, J.-P., Zhou, X., Moore, J., Havlir, D. V., Fridland, G., Tierney, C., Smeaton, L., Fox, L., Richman, D., Polland, R. and the ACTG 290 Team: Impairment of stavudine phosphorylation in patients receiving a combination of zidovudine and stavudine. Abstr.; 5th Conference on Retroviruses and Opportunistic Infections, Chicago, USA, February 1998.

  6. Back, D. J., Hoggard, P. G., Gibbons, S. E., Lloyd, J., Khoo, S. H., Wilkins, E. G., Merry, C., Barry, M. G., Dann, L., Loveday, C.: Zidovudine (ZDV) phosphorylation determined at intervals over 12 months in naive and antiretroviral experineced HIV+patients. Abstr. 42260; 12th World AIDS Conference, Geneva, Switzerland, July 1998.

  7. Arner, E. S. J., Valentin, A., Eriksson, S.: Thymidine and 3′-azido-3′-deoxythmidine metabolism in human peripheral blood lymphocytes and monocytes-derived macrophages. J. Biol. Chem. 267 (1992) 10968–10975.

    PubMed  CAS  Google Scholar 

  8. Phiboonbanakit, D., Lloyd, J., Khoo, S., Wilkins, E., Maher, B., Barry, M., Back, D.: Quantification of d4T triphosphate in ZDV naive and ZDV experienced HIV infected individuals by an enzymatic assay. Abstr.; 6th Conference on Retroviruses and Opportunistic Infections, Chicago, USA, February 1999.

  9. Gao, W. Y., John, D. G., Mitsuya, H.: Anti-human immunodeficiency virus type 1 activity of hydroxyurea in combination with 2′,3′-dideoxynucleosides. Mol. Pharmacol. 46 (1994) 767–772.

    PubMed  CAS  Google Scholar 

  10. Gottesman, M. M., Pastan, I.: Biochemistry of multidrug resistance mediated by the multidrug transporter. Ann. Rev. Biochem. 62 (1993) 385–427.

    Article  PubMed  CAS  Google Scholar 

  11. Kim, R. B., Fromm, M. F., Wandel, C., Leake, B., Wood, A. J. J., Roden, D. M., Wilkinson, G. R.: The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J. Clin. Invest. 101 (1998) 289–294.

    Article  PubMed  CAS  Google Scholar 

  12. Lee, C. G. L., Gottesman, M. M., Cardarelli, C. O., Ramachandra, M., Jeang, K. T., Ambudkar, S. V., Pastan, I., Dey, S.: HIV-1 protease inhibitors are substrates for the MDR-1 multidrug transporter. Biochem. J. 37 (1998) 3594–3601.

    Article  CAS  Google Scholar 

  13. Washington, C. B., Duran G. E., Sikic, B. I., Blaschke, T. F.: Saquinavir is a high affinity substrate for the multidrug transporter P-glycoprotein. Clin. Pharmacol. Ther. 61 (1997) 193.

    Google Scholar 

  14. Srinivas, R. V., Middlemas, D., Flynn, P., Fridland, A.: Human immunodeficiency virus protease inhibitors serve as substrates for multidrug transporter proteins MDR1 and MRP1 but retain antiviral efficacy in cell lines expressing these transporters. Antimicrob. Agents Chemother. 42 (1998) 3157–3162.

    PubMed  CAS  Google Scholar 

  15. Washington, C. B., Duran, G. E., Man, M. C., Sikic, B. I., Blaschke, T. F.: Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells. Acquir. Immune Defic. Syndr. Human Retrovirol. 19 (1998) 203–209.

    CAS  Google Scholar 

  16. Profit, L., Brooks, B., Williams, D. P., Back, D. J.: Modulation of Pglycoprotein function in human peripheral mononuclear cells by saquinavir. Br. J. Clin. Pharmacol. 46 (1998) 295P.

  17. Drach, D., Zhao, S., Drach, J., Mahadevia, R., Gattringer, C., Andreeff, M.: Subpopulations of normal peripheral blood and bone marrow cells express and functional multidrug resistant phenotype. Blood 80 (1992) 2729–2734.

    PubMed  CAS  Google Scholar 

  18. Lucia, M. B., Cauda, R., Landay, A. L., Malorni, W., Donelli, G.: Transmembrane P-glycoprotein (P-gp/P-170) in HIV infection: analysis of lymphocyte surface expression and drug unrelated function. AIDS Res. Hum. Retroviruses 11 (1995) 893–901.

    Article  PubMed  CAS  Google Scholar 

  19. Kaczorowski, S., Ochocka, M., Kaczorowska, M., Aleksandrowicz, R., Matysiakl, M., Karwacki, M.: Is P-glycoprotein a sufficient marker for multidrug resistancein vivo-immunohistochemical staining for P-glycoprotein in children and adult leukaemia. Leuk. Lymphoma 20 (1995) 143–152.

    PubMed  CAS  Google Scholar 

  20. Kobayashi, Y., Wantanabe, N., Oshimi, K.: Expression of multidrug resistance P-glycoprotein on peripheral blood mononuclear cells of patients with granular lymphocyte proliferative disorders. Leuk. Lymphoma 14 (1994) 157–161.

    PubMed  CAS  Google Scholar 

  21. Goldstein, L. J., Pastan, I., Gottesman, M. M.: Multidrug resistance in human cancer. Crit. Rev. Oncol. Hematol. 12 (1992) 243–253.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dept. of Pharmacology and Therapeutics, University of Liverpool, Ashton St., L69 3GE, Liverpool, UK

    D. J. Back Ph.D.

Authors
  1. D. J. Back Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Back, D.J. Pharmacological issues relating to viral resistance. Infection 27 (Suppl 2), S42–S44 (1999). https://doi.org/10.1007/BF02561671

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02561671

Keywords

Search

Navigation